Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis.

"CONFLICTS OF INTEREST Guarantor of the article: Ikuo Hirano, MD. Specific author contributors: Conceptualization: E.S.D. Data curation: I.H. and S.Z. Investigation: I.H. and E.S.D. Methodology: E.B., E.S.D., S.Z., C.M.C., and K.S.C. Project administration: I.H. Supervision: I.H. Writing–original draft: I.H., S.Z., C.D.O., and C.M.C. Writing–review and editing: All authors. Financial support: This study was supported by Bristol Myers Squibb. Writing and editorial assistance were provided by Claire Jarvis, PhD, and John Simmons, MD, of Peloton Advantage, an OPEN Health company, funded by Bristol Myers Squibb. Potential competing interests: I.H. has served as a consultant for Ellodi/Adare, Allakos, Amgen, Arena, AstraZeneca, Celgene/Receptos/Bristol Myers Squibb, Esocap, Gossamer Bio, Nextsone, Parexel/Calyx, Regeneron/Sanofi, and Shire/Takeda and has received grant/research support from Ellodi/Adare, Allakos, Celgene/Receptos/Bristol Myers Squibb, Sanofi/Regeneron, and Shire/Takeda. M.E.R. has served as a consultant to Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Nextstone One, Bristol Myers Squibb, AstraZeneca, Ellodi Pharma, GlaxoSmithKline, Regeneron/Sanofi, Revolo Biotherapeutics, and Guidepoint; has an equity interest in Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, and Nextstone One; and receives royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children's Hospital. S.Z, C.d.O., and C.M.C. are employees of Bristol Myers Squibb. K.S.C. and E.D.B. are employees of Evidera. E.S.D. has served as a consultant for Abbott, AbbVie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv, Salix, Sanofi, and Shire/Takeda; has received grant/research support from Adare/Ellodi, Allakos, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/Bristol Myers Squibb, Regeneron, and Shire/Takeda; and has received educational grants from Allakos, Banner, and Holoclara."

"Financial support: This study was supported by Bristol Myers Squibb. Writing and editorial assistance were provided by Claire Jarvis, PhD, and John Simmons, MD, of Peloton Advantage, an OPEN Health company, funded by Bristol Myers Squibb."